EARTH CITY, Mo. — Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, points to its role in taking a patient-first approach for providing personalized medicine as a more precise basis to predict the prognosis of genetic diseases. This model recognizes the important, growing role of personalized medicine, an evolving field in which physicians use diagnostic tests to identify specific, often genetic, biological markers, to help determine which medical treatments and procedures will work best for each patient. Listen to the “Rare Voices” podcast series here.

“Personalized health care has the capacity to detect the onset of disease at its earliest stages, pre-empt the progression of disease and increase the efficiency of the health care system by improving quality, accessibility and affordability,” says Donovan Quill, president and CEO, Optime Care. “As health care shifts from one-size-fits-all, trial-and-error medicine toward a more targeted approach, physicians will rely more on a patient’s molecular information.”

For its pharmaceutical partners that are developing and commercializing personalized drugs for orphan and ultra-orphan diseases, the Optime Care approach streamlines patient enrollment in clinical trials, maximizes interaction with patients for adherence and compliance, hastens time to commercialization and provides continuity of care to avoid lapses in therapy.

“Optime Care is at the forefront of meeting the needs of individual patients with rare disorders, offering an innovative and unique model designed to optimize data related to personalized medicine in order to enhance and inform health care decisions,” says Quill.